{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
penicillin v
to a specific field?
Status:
Investigational
Source:
NCT01440517: Phase 2 Interventional Terminated Diabetes Mellitus
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Maraciclatide Tc-99m is radiolabelled with technetium 99m cyclic peptide maraciclatide (NC100692 or diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol). Maraciclatide Tc-99m binds vitronectin receptors (αvβ3 and αvβ5 integrins) with high affinity. Maraciclatide Tc-99m is used in single-photon emission computed tomography (SPECT) imaging of vitronectin receptors that are upregulated and expressed preferentially on proliferating endothelial cells. Maraciclatide Tc-99m is being developed as a diagnostic agent to determine neoplasia and cardiovascular diseases.
Status:
Investigational
Source:
NCT03202303: Phase 2 Interventional Recruiting Autism Spectrum Disorder
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cannabidivarin is a homolog of cannabidiol, with a well-established antiepileptiform profile in preclinical studies, both in vitro and in vivo animal models of epilepsy. The oral bioavailability of cannabidivarin is very low (about 6%) due to erratic absorption and first pass metabolism. After oral administration, the maximum plasma concentration of Cannabidivarin is rising in about three hours and the drug has a large volume of distribution, because of his link to protein plasma, being highly liposoluble, so CBDV can penetrate well to the brain. Cannabidivarin is also metabolized in the liver to 7-COOH and 6-OH metabolites, but the mechanism is also unknown. There is an ongoing phase II double-blind, placebo-controlled trial that is assessing the efficacy and safety of cannabidivarin in Children With Autism Spectrum Disorder (ASD).
Class (Stereo):
CHEMICAL (ABSOLUTE)
Naglivan [PMD 501, vanadeine] is a vanadyl organometallic agent, in the preclinical phase of development in France, with Pan Medica, as an orally-active drug for the treatment of diabetes mellitus. Naglivan is an orally effective form of vanadyl with an oral potency 7.6 times greater than that of vanadyl sulfate (minimum effective dose: 0.06 mmol vanadium.kg-1.day-1) as compared to vanadyl sulfate (0.46 mmol vanadium.kg-1.day-1). The lack of incidence of diarrhea in either control or diabetic animals demonstrates that naglivan could be a more therapeutically desirable form of vanadyl.
Status:
Investigational
Source:
NCT02350426: Phase 1 Interventional Terminated Arthritis, Rheumatoid
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Flutriciclamide F18 (18F-GE-180), a translocator protein (TSPO)-PET radiotracer was used using in different pathologies. This agent was studied in phase I clinical trial to assess inflammation in rheumatoid arthritis. However, this study was terminated because of the pre-defined stopping criteria in the protocol.
Status:
Investigational
Source:
NCT01951222: Phase 2 Interventional Completed Asthma
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
(R)-Mequitazine or V0162 (10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine) is an anticholinergic enantiomer of mequitazine, an existing oral racemic antihistamine commercialized for over 30 years. (R)-Mequitazine was found to be an antagonist at muscarinic acetylcholine receptors behaving as an inverse agonist. (R)-Mequitazine was investigated in clinical trials for the treatment of chronic obstructive pulmonary disease, asthma and urinary incontinence.
Status:
Investigational
Source:
NCT02965118: Phase 3 Interventional Completed Atopic Dermatitis
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
PAC-14028 was developed as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. It is known that TRPV1 might be deeply associated with skin permeability barrier function, suggesting that modulation of TRPV1 might be beneficial for the skin disorders with barrier damages. Amorepacific developed a topical cream formulation of PAC-14028. This drug completed phase III clinical trial for the treatment of atopic dermatitis. In addition, PAC-14028 participated in phase II clinical trials to evaluate its safety and efficacy in seborrheic dermatitis and in rosacea. Moreover, PAC-14028 has been used in trials studying the treatment of pruritus.
Status:
Investigational
Source:
NCT03691207: Phase 2 Interventional Completed Adenoid Cystic Carcinoma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
BMS-906024 is a lead candidate of a series of inhibitors of gamma secretase-mediated Notch signalling. BMS-906024 is an orally bioavailable, small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor BMS-906024 binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth. BMS-906024 is currently in Phase 1 clinical trials for patients with T-cell acute lymphoblastic leukemia and metastatic solid tumors, including lung cancer.
Status:
Investigational
Source:
NCT02377336: Phase 2 Interventional Withdrawn Ischemic Heart Disease
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Eleclazine (formerly known as GS-6615) is a dihydrobenzoxazepinone selective cardiac late sodium current inhibitor. Gilead Sciences is developing eleclazine as an oral treatment for long QT syndrome, hypertrophic cardiomyopathy, ischaemic heart disease, and Ventricular arrhythmias.
Status:
Investigational
Source:
NCT01424397: Phase 2 Interventional Completed Rhinitis
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
SB-705498 is a selective vanilloid receptor-1 (VR1/TRPV1) antagonist developed by GlaxoSmithKline. The drug was tested in phase II of clinical trials for the treatment of pain (dental, rectal, in migraine) and rhinitis/cough. The development of the drug has been terminated by unknown reason (SB-705498 is no longer in GSK pipeline).
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
